Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
25.040
Open
25.040
VWAP
24.99
Vol
629.21K
Mkt Cap
1.17B
Low
24.950
Amount
15.72M
EV/EBITDA(TTM)
13.85
Total Shares
46.82M
EV
1.21B
EV/OCF(TTM)
32.82
P/S(TTM)
1.63
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
Show More

Events Timeline

(ET)
2026-04-14
16:20:00
Major Averages Rise on Renewed U.S.-Iran Diplomacy Optimism
select
2026-04-14
12:00:00
Major U.S. Averages Broadly Higher, Nasdaq Up 1.66%
select
2026-04-14
06:10:00
Avanos Acquired by American Industrial Partners for Approximately $1.27B
select
2026-02-24 (ET)
2026-02-24
07:10:00
Company Reports Q4 Revenue of $180.9M
select
2026-02-24
07:10:00
Sees 2026 Revenue at $700M-$720M
select
2026-01-20 (ET)
2026-01-20
08:10:00
Avanos Medical and Siemens Healthineers Announce Strategic Co-Marketing Agreement
select
2025-11-05 (ET)
2025-11-05
11:38:10
Avanos increases FY25 adjusted EPS forecast to 85c-95c, up from 75c-95c
select

News

PRnewswire
7.0
06-12PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Targeted Companies: Halper Sadeh LLC is investigating Avanos Medical, Inc., Nuvalent, Inc., XOMA Royalty Corporation, and TruBridge, Inc. for potential violations of federal securities laws or breaches of fiduciary duties, including Avanos's sale to American Industrial Partners for $25.00 per share.
  • Shareholder Rights: Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options, with the firm offering to handle matters on a contingent fee basis, emphasizing its commitment to protecting shareholder interests.
  • Potential Benefits: The investigation may lead to increased consideration or additional disclosures for shareholders, indicating Halper Sadeh LLC's dedication to securing better financial outcomes and transparency for investors.
  • Legal Advocacy: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct cases, having successfully recovered millions for defrauded investors, showcasing its expertise in safeguarding investor rights.
Globenewswire
8.5
06-11Globenewswire
Monteverde Law Firm Investigates Multiple Acquisition Cases
  • Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Taylor Morrison Home Corp. by Berkshire Hathaway, with shareholders expected to receive $72.50 per share in cash, potentially providing significant financial returns for investors.
  • Caesars Entertainment Transaction: In the deal with Fertitta Gaming Holdco, Caesars shareholders are anticipated to receive $31.00 per share in cash along with a ticking consideration, which could enhance shareholder returns over time.
  • XOMA Shareholder Gains: XOMA Royalty Corporation's sale to Ligand Pharmaceuticals will see shareholders receiving $39.00 per share in cash, offering a clear and immediate financial benefit to investors.
  • Avanos Medical Acquisition: Avanos Medical, Inc. is set to provide shareholders with $25.00 per share in cash from its sale to American Industrial Partners, with a shareholder vote scheduled for July 22, 2026, to finalize the transaction.
PRnewswire
7.0
06-01PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Investigation Focus: Halper Sadeh LLC is investigating Caesars Entertainment, Inc. (NASDAQ:CZR) regarding its sale to Fertitta Entertainment, Inc. for $31.00 per share, which may infringe on shareholder rights, prompting shareholders to consider their options.
  • Shareholder Rights Protection: The firm is also scrutinizing Avanos Medical, Inc. (NYSE:AVNS) for its sale to American Industrial Partners at $25.00 per share, which could limit superior competing offers, encouraging shareholders to understand their rights.
  • Global Business Travel Group: Halper Sadeh LLC is investigating Global Business Travel Group, Inc. (NYSE:GBTG) for its sale to Long Lake Management at $9.50 per share, potentially harming shareholders, and advises them to contact the firm for more information.
  • Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders are not responsible for legal fees upfront, aiming to provide legal support for affected investors and seek corporate reforms and compensation.
Globenewswire
8.5
06-01Globenewswire
Investigation Alerts for Multiple Company Acquisitions
  • Avanos Medical Acquisition Investigation: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in a deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
  • Global Business Travel Group Acquisition: Amex GBT will be acquired by Long Lake Management for $9.50 per share in an all-cash transaction valued at around $6.3 billion, with investigations examining if the board failed to conduct a fair process, potentially impacting shareholder interests.
  • Equity Residential Merger Investigation: Equity Residential will merge with AvalonBay Communities, with AvalonBay shareholders receiving 2.793 shares of Equity Residential for each share owned, and investigations are looking into whether the board ensured a fair process, affecting shareholder rights.
  • LiveRamp Acquisition Review: LiveRamp is to be acquired by Publicis Groupe for $38.50 per share, totaling an enterprise value of $2.167 billion, with investigations questioning if the board fulfilled fiduciary duties to ensure a fair transaction for shareholders.
Globenewswire
8.5
05-05Globenewswire
Investigation Alerts for Multiple Company Mergers
  • Helix Merger Investigation: Helix Energy Solutions is set to be acquired by Hornbeck Offshore Services, with Helix shareholders expected to own approximately 45% of the combined entity, raising concerns about whether the Helix Board breached fiduciary duties by failing to ensure a fair process in the transaction.
  • TopBuild Acquisition Details: TopBuild will be acquired by QXO, allowing shareholders to choose between $505 in cash or 20.2 shares of QXO stock per TopBuild share, with the deal's total consideration being approximately 45% cash and 55% stock, prompting investigations into whether the transaction offers fair value, especially as it falls below the 52-week high of $559.47.
  • Avanos Acquisition Situation: Avanos is being acquired by American Industrial Partners for $25.00 per share, amounting to an enterprise value of approximately $1.272 billion, with investigations focusing on whether the Avanos Board failed to conduct a fair process to ensure shareholder value in the deal.
  • Affinity Bancshares Transaction: Affinity Bancshares will be acquired by Fidelity for $23.00 per share, representing a total transaction value of approximately $142.8 million, with investigations examining whether the Board breached fiduciary duties by not ensuring the fairness of the transaction for shareholders.
Globenewswire
8.5
05-05Globenewswire
Class Action Developments for Multiple Companies' Shareholders
  • XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
  • RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
  • Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
  • Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.

Valuation Metrics

The current forward P/E ratio for Avanos Medical Inc (AVNS.N) is 30.67, compared to its 5-year average forward P/E of 16.93. For a more detailed relative valuation and DCF analysis to assess Avanos Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
16.93
Current PE
30.67
Overvalued PE
22.29
Undervalued PE
11.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.02
Current EV/EBITDA
15.67
Overvalued EV/EBITDA
16.57
Undervalued EV/EBITDA
-2.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.39
Current PS
1.58
Overvalued PS
1.83
Undervalued PS
0.96

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of stocks to daytrade
Intellectia · 53 candidates
Market Cap: >= 50.00MPrice: $2.00 - $100.00New High Low: 52w_High, 52w_LowList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
WULF logo
WULF
Terawulf Inc
8.25B
AVNS logo
AVNS
Avanos Medical Inc
675.76M
CAG logo
CAG
Conagra Brands Inc
6.94B
HST logo
HST
Host Hotels and Resorts, Inc
13.93B
ASX logo
ASX
ASE Technology Holding Co Ltd
59.12B
APLS logo
APLS
Apellis Pharmaceuticals Inc
5.22B
Stocks Bullish Tomorrow
Intellectia · 75 candidates
Moving Average Relationship: PriceAboveMA20Option Sentiments: BullishOne Day Rise Prob: >= 60One Day Predict Return: >= 1.0%Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
EHAB logo
EHAB
Enhabit Inc
554.91M
FET logo
FET
Forum Energy Technologies Inc
526.00M
BLFY logo
BLFY
Blue Foundry Bancorp
293.98M
GSBC logo
GSBC
Great Southern Bancorp Inc
704.33M
GORO logo
GORO
Gold Resource Corp
242.79M
AVNS logo
AVNS
Avanos Medical Inc
641.97M

Whales Holding AVNS

B
Blackhill Capital, Inc
Holding
AVNS
+12.77%
3M Return
A
Armistice Capital LLC
Holding
AVNS
+9.30%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Avanos Medical Inc (AVNS) stock price today?

The current price of AVNS is 24.98 USD — it has decreased -0.2

What is Avanos Medical Inc (AVNS)'s business?

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

What is the price predicton of AVNS Stock?

Wall Street analysts forecast AVNS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVNS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Avanos Medical Inc (AVNS)'s revenue for the last quarter?

Avanos Medical Inc revenue for the last quarter amounts to 182.20M USD, increased 8.78

What is Avanos Medical Inc (AVNS)'s earnings per share (EPS) for the last quarter?

Avanos Medical Inc. EPS for the last quarter amounts to 0.11 USD, decreased -21.43

How many employees does Avanos Medical Inc (AVNS). have?

Avanos Medical Inc (AVNS) has 2287 emplpoyees as of June 13 2026.

What is Avanos Medical Inc (AVNS) market cap?

Today AVNS has the market capitalization of 1.17B USD.